Adagene Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADAG research report →
Range $10 – $10
Price Chart
About the company
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials.
- CEO
- Peter Luo
- IPO
- 2021
- Employees
- 128
- HQ
- Suzhou, JS, CN
Get TickerSpark's AI analysis on ADAG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $153.98M
- P/E
- -8.67
- PEG
- -0.09
- P/S
- 16.53
- P/B
- 1.75
- EV/EBITDA
- -1.47
- Div Yield
- 0.00%
- Gross Margin
- 94.22%
- Op Margin
- -240.31%
- Net Margin
- -220.66%
- ROE
- -29.09%
- ROIC
- -19.62%
Latest fiscal year · YoY change
- Revenue
- $7.67M+7332.8%
- Gross Profit
- $7.67M+1032.0%
- Op Income
- $-21,438,295
- Net Income
- $-17,609,413+47.3%
- EPS
- $-0.46+51.3%
- OCF Growth
- +47.3%
- FCF Growth
- +47.3%
- 52W High
- $4.85
- 52W Low
- $1.30
- 50D MA
- $3.82
- 200D MA
- $3.10
- Beta
- 0.58
- RSI (14)
- 58
- Avg Volume
- 282.32K
No earnings-call transcripts are available for ADAG yet.
- Free Float
- 71.7%
- Shares Outstanding
- 37.65M
- Float Shares
- 26.99M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mill Creek Capital Advisors, LLC | 199.61K | 0 |
Held by 1 ETFs
Biggest fund positions in ADAG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | DO CUONG V | buy | 2,000 |
| Aug 13, 26 | Zhu Li | other | 20,000 |
| Aug 13, 26 | Cheung Andy Yiu Leung | other | 20,000 |
| Aug 13, 26 | DO CUONG V | other | 20,000 |
| Aug 13, 26 | Grawunder Ulf | other | 20,000 |
| Aug 5, 26 | Luo Peter | buy | 279 |
| Aug 4, 26 | Luo Peter | buy | 22,966 |
| Mar 18, 26 | Chane-Du Mickael Yannick | other | 0 |
| Mar 18, 26 | Chane-Du Mickael Yannick | other | 0 |
| Mar 18, 26 | Chane-Du Mickael Yannick | other | 400,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADAG coverage
Recent articles, reports, and earnings notes.
No research on ADAG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADAG report →Adagene to Participate in Three Upcoming Investor Conferences
globenewswire.com · Aug 20
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
globenewswire.com · Aug 12
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
zacks.com · Jun 5
Are Medical Stocks Lagging Adagene (ADAG) This Year?
zacks.com · Jun 2
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
marketbeat.com · May 19
Adagene to Participate in Two Upcoming Investor Conferences
globenewswire.com · May 12
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Growth in Short Interest
defenseworld.net · Apr 26
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
globenewswire.com · Apr 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.